A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
D000293:Adolescent; D000328:Adult; D000374:Aggression / Q000187:drug effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy / Q000209:etiology; D001066:Appetite / Q000187:drug effects; D001321:Autistic Disorder / Q000150:complications / Q000188:drug therapy*; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000150:complications / Q000188:drug therapy*; D002675:Child, Preschool; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced; D005260:Female; D006801:Humans; D007508:Irritable Mood / Q000187:drug effects; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000078785:Mirtazapine; D016728:Self-Injurious Behavior / Q000188:drug therapy / Q000209:etiology; D012720:Severity of Illness Index; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy / Q000209:etiology; D015430:Weight Gain / Q000187:drug effects